The book explores role of small molecules and peptides in cancer therapy, with a focus on (Aptamer-drug conjugates, Androgen Receptor and Tyrosine Kinase inhibitors, and Glycosylation inhibitors. Small molecule inhibitors targeting oncogenic pathways such as EGFR and PI3K inhibitors, Peptides in oral cancer such as Antimicrobial peptides, Cell Penetrating Peptides, Tumour targeting peptides, Natural small molecules with anti-cancer effects such as phenolic compounds, alkaloids, terpenoids and steroids, Phthalides and lectins, Peptides targeting the tumor microenvironment such as GM-CSF's, LAG3, PD 1, CCL2, CCR-5, CXCR4 inhibitors). An introductory chapter covers the foundation for understanding their significance in cancer treatment. The book delves into the versatility and precision of small molecules, highlighting their advantages in drug delivery and formulation strategies. It emphasizes the expansion of therapeutic horizons through small molecule peptides, shedding light on their potential in targeting tumor microenvironments and advancing cancer therapeutics. Additionally, the book discusses combination therapies and synergistic effects, offering a deeper understanding of integrating different therapeutic approaches. Furthermore, it addresses emerging trends, challenges, safety considerations, and the relevance of small-molecule inhibitors.
This book provides a crucial update on the latest advancements and serves as a valuable resource for researchers, clinicians, and students interested in the rapidly evolving landscape of cancer treatment, offering an overview of the potential and complexities associated with these compounds in the fight against cancer.
